Systemic Mastocytosis: Symptoms, Diagnosis & Treatment
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of patients taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- These findings primarily impact individuals with obesity *and* pre-existing cardiovascular disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated significant weight loss, the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
Key Findings: The Numbers Tell the Story
The study found that 6.5% of patients taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Importantly, the weight loss achieved with semaglutide – an average of approximately 15% of initial body weight – did *not* appear to offset this cardiovascular risk. The findings were especially pronounced in patients with a history of heart failure.
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 1.5% | 1.2% |
| Non-Fatal Stroke | 1.7% | 1.3% |
| Non-fatal Heart Attack | 3.4% | 2.4% |
| MACE (Combined) | 6.5% | 4.9% |
Who is Affected? Understanding Patient Risk
These findings primarily impact individuals with obesity *and* pre-existing cardiovascular disease. This includes those with a history of heart attack, stroke, peripheral artery disease, or heart failure. The trial did *not* include patients with type 2 diabetes, raising questions about whether the cardiovascular risk profile differs in that population.Individuals without established heart disease likely face a different risk-benefit calculation, but further research is needed to clarify this.
It’s crucial to differentiate between correlation and causation. the SELECT trial demonstrates an *association* between semaglutide use and increased cardiovascular events, but doesn’t definitively prove that the drug *caused* these events. Other factors, such as underlying health conditions and lifestyle choices, could contribute to the observed risk.